Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis

American Journal of Veterinary Research

Volumn 69, Issue 3, 2008, Pages 410-415

  Regnier, Alain ^a   Schneider, Marc ^b   Concordet, Didier ^a   Toutain, Pierre Louis ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Vétoquinol Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MARBOFLOXACIN;

ANIMAL DISEASE; ANIMAL EXPERIMENT; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; ENDOPHTHALMITIS; ESCHERICHIA COLI; EYE INFECTION; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RABBIT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; ENDOPHTHALMITIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; QUINOLONES; RABBITS; VITREOUS BODY;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; ORYCTOLAGUS CUNICULUS;

EID: 41049108841     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.3.410     Document Type: Article

References (50)

1. Whitley RD. Canine and feline primary ocular bacterial infections. Vet Clin North Am Small Anim Pract 2000;30:1151-1167.
2. Peiffer RL, Cook CS, Möller I. Therapeutic strategies involving antimicrobial treatment of ophthalmic disease in small animals. J Am Vet Med Assoc 1984;185:1172-1175.
3. Dowling PM, Grahn BH. Antimicrobial therapy of ocular infections. Can Vet J 1998;39:121-124.
4. Sunaric-Mégevand G, Pournaras CJ. Current approaches to postoperative endophthalmitis. Brit J Ophthalmol 1997; 81:1006-1015.
5. Kresloff MS, Castellarin AA, Zarbin MA. Endophthalmitis. Surv Ophthalmol 1998;43:193-224.
6. Smith PJ. Surgery of the canine posterior segment. In: Gelatt KN, ed. Veterinary ophthalmology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999;935-980.
7. Davis JL. Intravenous antibiotics for endophthalmitis. Am J Ophthalmol 1996;122:724-726.
8. Rowley RA, Rubin LF. Penetration of penicillin into the aqueous humor in the dog. Am J Vet Res 1969;30:1945-1950.
9. Sigel CW, Macklin AW, Grace ME, et al. Trimethoprim and sulfadazine concentrations in aqueous and vitreous humors of the dog. Vet Med Small Anim Clin 1981;76:991-993.
10. Regnier A, Concordet D, Schneider M, et al. Population pharmacokinetics of marbofloxacin in aqueous humor after intravenous administration in dogs. Am J Vet Res 2003;64:889-893.
11. Barza M. Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation. Scand J Infect Dis Suppl 1978;14:151-159.
12. Meredith TA. Antimicrobials and antifungals. In: Zimmerman TJ, Kooner KS, Sharir M, eds. Textbook of ocular pharmacology. Philadelphia: Lippincott Raven, 1997;363-385.
13. Giamarellou H, Kanellas D, Kavouldis E, et al. Comparative pharmacokinetics of ciprofloxacin, ofloxacin and pefloxacin in human aqueous humour. Eur J Clin Microbiol Infect Dis 1993;12:293-297.
14. Madu AA, Mayers M, Perkins R, et al. Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. Exp Eye Res 1996;63:129-136.
15. Behrens-Baumann W, Martell J. Ciprofloxacin concentrations in human aqueous humor following intravenous administration. Chemotherapy 1987;33:328-330.
16. Donnenfeld ED, Perry HD, Snyder RW, et al. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol 1997;115:173-176.
17. Salvanet A, Fisch A, Lafaix C, et al. Pefloxacin concentrations in human aqueous humour and lens. J Antimicrob Chemother 1986;18:199-201.
18. Bron AM, Pechinot AP, Garcher CP, et al. The ocular penetration of oral sparfloxacin in humans. Am J ophthalmol 1994;117:322-327.
19. Kobayakawa S, Tochikubo T, Tsuji A. Penetration of levofloxacin into human aqueous humor. Ophthalmic Res 2003;35:97-101.
20. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol 2003;121:345-350.
21. Hariprasad SM, Shah GK, Mieler WF, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol 2006;124:178-182.
22. Spreng M, Deleforge J, Thomas V, et al. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. J Vet Pharmacol Ther 1995;18:284-289.
23. Cester CC, Schneider M, Toutain PL. Comparative kinetics of two orally administered quinolones in the dog: enrofloxacin versus marbofloxacin. Rev Med Vet (Toulouse) 1996;143:703-716.
24. Schneider M, Thomas V, Boisramé B, et al. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J Vet Pharmacol Ther 1996;19:56-61.
25. Heinen E. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin and orbifloxacin in dogs after single oral administration. J Vet Pharmacol Ther 2002;25:1-5.
26. Csukas S, Paterson CA, Brown K, et al. Time course of rabbit ocular inflammatory response and mediator release after intravitreal endotoxin. Invest Ophthalmol Vis Sci 1990;31:382-387.
27. Allen JB, McGahan MC, Ferrell JB, et al. Nitric oxide synthase inhibitors exert differential time-dependent effects on LPS-induced uveitis. Exp Eye Res 1996;62:21-28.
28. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1998;16:303-309.
29. Walstad RA, Blika S, Thurmann-Nielsen E, et al. The penetration of ceftazidime into the inflamed rabbit eye. Scand J Infect Dis 1987;19:131-135.
30. Drusano GL, Liu W, Perkins R, et al. Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program. Antimicrob Agents Chemother 1995;39:1683-1687.
31. Alfaro DV, Hudson SJ, Rafanan MM, et al. The effect of trauma on the ocular penetration of intravenous ciprofloxacin. Am J Ophthalmol 1996;122:678-683.
32. El-Massry A, Meredith TA, Aguilar HE, et al. Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration. Am J Ophthalmol 1996;122:684-689.
33. Meredith TA, Aguilar HE, Shaarawy A, et al. Vancomycin levels in the vitreous cavity after intravenous administration. Am J Ophthalmol 1995;119:774-778.
34. Öztürk F, Kurt E, Inan ÜÜ, et al. A. Penetration of topical and oral ofloxacin into the aqueous and vitreous humor of inflamed rabbit eyes. Int J Pharm 2000;204:91-95.
35. Waga J, Nitsson-Ehle I, Ljungberg B, et al. Microdialysis for pharmacokinetic studies of ceftazidime in rabbit vitreous. J Ocul Pharmacol Ther 1999;15:455-463.
36. Kulkarni PS, Mancino M. Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res 1993;56:275-279.
37. Barza M. Animal models in the evaluation of chemotherapy of ocular infections. In: Zak O, Sande MA, eds. Experimental models in antimicrobial chemotherapy. Vol 1. London: Academic Press, 1986;185-211.
38. Fukuda M, Sasaki K. Different iris coloration and uptake of a fluoroquinolone agent into the iris ciliary body of rabbit eyes. Ophthalmic Res 1994;26:137-140.
39. Perez S, Solans C, Bregante MA, et al. Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits. J Antimicrob Chemother 2002;50:541-545.
40. Gruet P, Richard P, Thomas E, et al. Prevention of surgical infections in dogs with a single intravenous injection of marbofloxacin: an experimental model. Vet Rec 1997;140:199-202.
41. Cochereau-Massin I, Bauchet J, Marrakchi-Benjaafar M, et al. Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. Antimicrob Agents Chemother 1993;37:633-636.
42. Liu W, Liu QF, Perkins R, et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob Agents Chemother 1998;42:1417-1423.
43. Iyer MN, He F, Wensel TG, et al. Clearance of intravitreal moxifloxacin. Invest Ophthalmol Vis Sci 2006;47:317-319.
44. Gatti G, Panozzo G. Effect of inflammation on intraocular penetration of intravenous ofloxacin in albino rabbits. Antimicrob Agents Chemother 1995;39:549-552.
45. Sanchez-Navarro A, Sanchez Recio MM. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methdology for dual dosage individualisation. Clin Pharmacokinet 1999;37:289-304.
46. Schentag JJ. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients. Am J Health-Syst Pharm 1999;56(suppl 3):S21-S24.
47. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995;28:143-160.
48. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999;58(suppl 2):29-36.
49. Meunier D, Acar J-F, Martel J-L, et al. A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets. Int J Antimicrob Agents 2004;24:592-598.
50. Yu-Speight AW, Kern TJ, Erb HN. Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract, surgery. Vet Ophthalmol 2005;8:181-187.